Published in Cancer Chemother Pharmacol on May 03, 2005
The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br J Pharmacol (2011) 0.92
Deletion of the STOP gene, a microtubule stabilizing factor, leads only to discrete cerebral metabolic changes in mice. J Neurosci Res (2008) 0.77
Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders. Int J Mol Sci (2017) 0.75
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell (2013) 4.45
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell (2013) 3.53
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A (2007) 2.34
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol (2006) 2.33
Prevalent positive epistasis in Escherichia coli and Saccharomyces cerevisiae metabolic networks. Nat Genet (2010) 2.16
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proc Natl Acad Sci U S A (2008) 2.16
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A (2003) 1.87
From structure to systems: high-resolution, quantitative genetic analysis of RNA polymerase II. Cell (2013) 1.87
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83
Dissection of DNA damage responses using multiconditional genetic interaction maps. Mol Cell (2012) 1.78
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets (2004) 1.72
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J (2008) 1.65
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Pax6 and engrailed 1 regulate two distinct aspects of renshaw cell development. J Neurosci (2004) 1.56
Postural model of sagittal spino-pelvic alignment and its relevance for lumbosacral developmental spondylolisthesis. Spine (Phila Pa 1976) (2008) 1.55
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol (2004) 1.55
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol (2005) 1.53
Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol (2002) 1.53
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 1.51
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res (2008) 1.47
Nanoarchitectonics: a conceptual paradigm for design and synthesis of dimension-controlled functional nanomaterials. J Nanosci Nanotechnol (2011) 1.47
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma. Leuk Res (2010) 1.47
The C60 formation puzzle "solved": QM/MD simulations reveal the shrinking hot giant road of the dynamic fullerene self-assembly mechanism. J Phys Chem B (2006) 1.46
Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. J Immunol (2009) 1.37
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
The genomic landscape and evolutionary resolution of antagonistic pleiotropy in yeast. Cell Rep (2012) 1.36
Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol (2012) 1.35
RYBP stabilizes p53 by modulating MDM2. EMBO Rep (2008) 1.33
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med (2008) 1.32
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate (2008) 1.31
Levels of change in adolescent sexual behavior in three Asian cities. Stud Fam Plann (2009) 1.31
CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol (2006) 1.31
p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets (2005) 1.30
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res (2005) 1.30
Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin Cancer Res (2006) 1.29
Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant (2004) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics (2002) 1.28
Classification of grass pollen through the quantitative analysis of surface ornamentation and texture. Proc Biol Sci (2013) 1.27
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res (2004) 1.25
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate (2003) 1.22
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
Combinatorial ShcA docking interactions support diversity in tissue morphogenesis. Science (2007) 1.20
Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest (2005) 1.19
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res (2010) 1.18
A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol (2013) 1.18
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res (2008) 1.17
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem (2010) 1.16
Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des (2012) 1.15
Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol (2005) 1.14
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res (2009) 1.13
Microarray analysis of gene expression in the liver during the urinary ethanol cycle in rats fed ethanol intragastrically at a constant rate. Exp Mol Pathol (2005) 1.13
Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol (2006) 1.13
NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine (2008) 1.12
Surgical utility of a new carbon dioxide laser fiber: functional and histological study. Laryngoscope (2005) 1.12
Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics (2008) 1.12
The role of laminin-integrin signaling in triggering MB formation. An in vivo and in vitro study. Exp Mol Pathol (2005) 1.10
Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One (2012) 1.09
Proteome analysis of leaves from the resurrection plant Boea hygrometrica in response to dehydration and rehydration. Planta (2006) 1.09
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst (2008) 1.09
Endofin, a FYVE domain protein, interacts with Smad4 and facilitates transforming growth factor-beta signaling. J Biol Chem (2007) 1.09
Modifications in P62 occur due to proteasome inhibition in alcoholic liver disease. Life Sci (2005) 1.08
Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination. Mol Pharmacol (2003) 1.07
Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats. Behav Brain Res (2011) 1.07
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett (2009) 1.07
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther (2006) 1.05
A rare case of rapid growth of exophytic gastrointestinal stromal tumor of the stomach. Dig Dis Sci (2005) 1.05
An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 1.04
9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett (2003) 1.03
Complexity of genome evolution by segmental rearrangement in Brassica rapa revealed by sequence-level analysis. BMC Genomics (2009) 1.02
Clotting factors and eicosanoids protect against nematode infections. J Innate Immun (2010) 1.02
Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kappaB pathways and mitochondrial protective mechanisms. Toxicology (2008) 1.02
Chronic intermittent fasting improves cognitive functions and brain structures in mice. PLoS One (2013) 1.00
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. J Pharm Biomed Anal (2010) 1.00
Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer (2009) 1.00